Savant Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Savant Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$851K	Buy	4,503 +461	+11%	+$80.6K	﹤0.01%	683
2025 Q4	$687K	Buy	4,042 +797	+25%	+$122K	﹤0.01%	708
2025 Q3	$428K	Buy	+3,245	New	+$389K	﹤0.01%	859
2025 Q2	–	Sell	-2,684	Closed	-$333K	–	1253
2025 Q1	$333K	Buy	2,684 +476	+22%	+$62.1K	﹤0.01%	801
2024 Q4	$272K	Buy	+2,208	New	+$260K	﹤0.01%	1158
2024 Q2	–	Sell	-12,462	Closed	-$1.5M	–	1308
2024 Q1	$1.5M	Buy	+12,462	New	+$1.53M	0.02%	425

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Savant Capital's JAZZ Position: Q1 2026 in Review

Savant Capital increased its Jazz Pharmaceuticals (JAZZ) stake by 11% in Q1 2026, buying an estimated $80.6K and bringing the position to 4,503 shares worth $851K. The position accounts for ﹤0.01% of the portfolio, ranked #683.

Savant Capital first reported a position in JAZZ in Q1 2024 and has held it in 6 quarters since. The position peaked at $1.5M in Q1 2024. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

Savant Capital held 4,503 shares of Jazz Pharmaceuticals worth $851K as of Q1 2026.
Savant Capital bought 461 Jazz Pharmaceuticals shares in Q1 2026, an estimated $80.6K.
Jazz Pharmaceuticals made up ﹤0.01% of Savant Capital's portfolio in Q1 2026, its #683 holding.
Savant Capital first reported a position in Jazz Pharmaceuticals in Q1 2024 and has held it in 6 quarters since.
Savant Capital's Jazz Pharmaceuticals position peaked at $1.5M in Q1 2024.
570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Savant Capital's 13F filing for Q1 2026, filed 4 May 2026.